Ceritinib
Ceritinib (LDK378) is a potent, orally active, and ATP-competitive small molecule inhibitor primarily targeting ALK with an IC50 of 200 pM, while also inhibiting IGF-1R, InsR, and STK22D. It demonstrates antitumor activity and is widely used in cancer research, particularly in studies of ALK-rearranged non-small cell lung cancer, both in vitro and in vivo.
Product Specifications
CAS Number
1032900-25-6
Product Name Alternative
Ceritinib, CD246, Cluster of differentiation 246, Anaplastic lymphoma kinase (ALK), Anaplastic lymphoma kinase, ALK, ALK tyrosine kinase receptor, inhibit, IGF-1R, IGF1R, Inhibitor, Insulin Receptor, LDK 378, LDK378, LDK-378, Serine Protease, SerineProtease, STK22D
Field of Research
Cardiovascular Research, Pharmacology & Drug Discovery, Protein Biochemistry, Signal Transduction
Purity
98.00% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:0.8 mg/mL (1.43 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:16 mg/mL (28.67 mM) ; Ethanol:3 mg/mL (5.37 mM)
Smiles
N (C1=C (OC (C) C) C=C (C (C) =C1) C2CCNCC2) C=3N=C (NC4=C (S (C (C) C) (=O) =O) C=CC=C4) C (Cl) =CN3
Molecular Formula
C28H36ClN5O3S
Molecular Weight
558.14
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
DEN40140 100 mL
Reagecon Density Standard Quality Range 0.9857 g/mL at 40°C
Sign In for Pricing
View Details 